703 related articles for article (PubMed ID: 20215503)
1. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.
Littlepage LE; Sternlicht MD; Rougier N; Phillips J; Gallo E; Yu Y; Williams K; Brenot A; Gordon JI; Werb Z
Cancer Res; 2010 Mar; 70(6):2224-34. PubMed ID: 20215503
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
3. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
4. Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Takahashi R; Amano H; Satoh T; Tabata K; Ikeda M; Kitasato H; Akira S; Iwamura M; Majima M
Biomed Pharmacother; 2014 Feb; 68(1):71-7. PubMed ID: 24291175
[TBL] [Abstract][Full Text] [Related]
5. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
6. [Matrix metalloproteinases and colorectal cancer].
Roeb E; Matern S
Med Klin (Munich); 2003 Dec; 98(12):763-70. PubMed ID: 14685678
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
8. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
[TBL] [Abstract][Full Text] [Related]
9. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines.
Shiraga M; Yano S; Yamamoto A; Ogawa H; Goto H; Miki T; Miki K; Zhang H; Sone S
Cancer Res; 2002 Oct; 62(20):5967-73. PubMed ID: 12384564
[TBL] [Abstract][Full Text] [Related]
10. Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate.
Delella FK; Justulin LA; Felisbino SL
Int J Androl; 2010 Feb; 33(1):e114-22. PubMed ID: 19508332
[TBL] [Abstract][Full Text] [Related]
11. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model.
Liu J; Tsao MS; Pagura M; Shalinsky DR; Khoka R; Fata J; Johnston MR
Lung Cancer; 2003 Dec; 42(3):335-44. PubMed ID: 14644522
[TBL] [Abstract][Full Text] [Related]
12. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
14. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
15. Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion.
Vosseler S; Lederle W; Airola K; Obermueller E; Fusenig NE; Mueller MM
Int J Cancer; 2009 Nov; 125(10):2296-306. PubMed ID: 19610062
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells.
Chen X; Su Y; Fingleton B; Acuff H; Matrisian LM; Zent R; Pozzi A
Int J Cancer; 2005 Aug; 116(1):52-61. PubMed ID: 15756690
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.
Dong Z; Bonfil RD; Chinni S; Deng X; Trindade Filho JC; Bernardo M; Vaishampayan U; Che M; Sloane BF; Sheng S; Fridman R; Cher ML
Am J Pathol; 2005 Apr; 166(4):1173-86. PubMed ID: 15793297
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis.
Blavier L; Lazaryev A; Dorey F; Shackleford GM; DeClerck YA
Cancer Res; 2006 Mar; 66(5):2691-9. PubMed ID: 16510589
[TBL] [Abstract][Full Text] [Related]
19. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.
Oh J; Takahashi R; Kondo S; Mizoguchi A; Adachi E; Sasahara RM; Nishimura S; Imamura Y; Kitayama H; Alexander DB; Ide C; Horan TP; Arakawa T; Yoshida H; Nishikawa S; Itoh Y; Seiki M; Itohara S; Takahashi C; Noda M
Cell; 2001 Dec; 107(6):789-800. PubMed ID: 11747814
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
